[ad_1]
PharmaCyte Biotech, Inc. (NASDAQ stock code:PMCB), a biotechnology company focused on the development of cell therapies for cancer and diabetes using its iconic cell-in-a-box packaging technology Cell-in-a-Box®, Today announced the start of a key study to determine whether PharmaCyte is used to treat locally advanced, inoperable pancreatic cancer-Cell-in-a-Box (CypCaps™) Combined with ifosfamide, a pro-cancer killer drug, can also delay the production and accumulation of malignant ascites. This is fluid that accumulates in the abdominal cavity due to various cancers.
Kenneth L. Waggoner, CEO of PharmaCyte, said: “We are keen to restart our malignant ascites project and resume our work on developing treatments for malignant ascites. We plan to conduct another preclinical study with Heidelberg Pharmaceuticals in Germany. The study mimics earlier studies showing that our cancer treatment can delay the production of malignant ascites. The cancer cells we will use in the study have been ordered, and the design of the protocol is in progress.
“Our medical and scientific advisory board chair, Dr. Matthias Löhr, is overseeing this research. We will use the same animal research model used by Dr. Löhr in the early research, which shows promise.”
Malignant ascites is the fluid secreted by abdominal tumors, including liver cancer, breast cancer, colon cancer, gastric cancer, bowel cancer, ovarian cancer, and uterine cancer. This liquid contains cancer cells, which can be seeded throughout the abdomen and form new tumors. Malignant ascites accumulates in the abdominal cavity, causing abdominal swelling, severe breathing difficulties and extreme pain. It must be in…
The full story on Benzinga.com
[ad_2]
Source link
